$19.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Semax 5mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Semax 5mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 80714-61-0 |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular Formula | C37H51N9O10S |
| Molecular Weight | 813.93 g/mol |
| Applications | Cognitive function research, neuroprotection studies, mood disorder investigations |
| Purity | ≥99% |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
Buy Semax for research is a documentation-led search intent, not a prompt for non-RUO application. This product-page guide frames Semax as a research-use-only peptide compound and focuses on identity, literature context, COA review, analytical testing, lot traceability, and supplier documentation [1]. Pure Lab Peptides presents this material for qualified research review and does not position Semax for consumption, diagnosis, wellness, or outcome-based claims.
Researchers evaluating where to buy Semax for research should first review RUO labeling, compound identity, batch-specific COA, lot traceability, peptide purity data, and analytical testing support. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. HPLC and LC-MS documentation can help support purity and identity review [11] [12].
Commercial research intent should turn into a technical review process. For Semax, that means checking whether the product listing, COA, label details, and batch records describe the same research material.
A safer way to handle “buy Semax” intent is to expand it into “buy Semax for research.” That keeps the page focused on research procurement, not personal decision-making.
Start with the documents that identify the material. The product listing should state the compound name, research-use-only status, lot number or batch reference, and whether a certificate of analysis is available.
The COA should then be reviewed against the product label. A mismatch between name, lot, or stated testing method should be resolved before the material is added to a laboratory record.
RUO labeling defines the intended lane of the product page. It helps separate laboratory research material from food, supplement, cosmetic, medical, or outcome-based positioning.
For Semax, RUO positioning also keeps literature discussion in the correct place. Published research can inform compound context, but the product page should remain about documentation, identity, and analytical review.
Semax is indexed by PubChem as ACTH (4-7), Pro-Gly-Pro, with CID 9811102, molecular formula C37H51N9O10S, and molecular weight of about 813.9 g/mol [1]. NCATS Inxight lists Semax under validated substance records and includes the preferred ACTH-fragment naming context [2].
Semax is commonly described in literature as a synthetic peptide and ACTH-fragment analog [3]. In plain terms, it is a seven-amino-acid peptide, not a broad wellness category or a consumer product class.
For research documentation, the core identity fields are the compound name, synonym set, CAS-related identifiers when available, formula, molecular weight, and sequence. Those fields help technical procurement teams compare a product listing against external identity records [1] [2].
The ACTH fragment context helps classify Semax as a peptide analog in neuropeptide research. One PubMed-indexed source describes Semax as an analogue of the N-terminal ACTH(4-10) fragment and notes its distinct classification compared with the parent hormone fragment [3].
This does not create a product claim. It simply gives researchers a way to check whether a supplier’s naming and documentation align with published chemical identity.
The Semax peptide sequence is commonly represented as Met-Glu-His-Phe-Pro-Gly-Pro, also shortened as MEHFPGP [2]. Sequence documentation matters because peptide identity depends on the correct amino acid order, not just the trade or catalog name.
A COA that only lists a name is less informative than a documentation set that connects the name to identity testing. Sequence, molecular weight, and analytical method notes should tell the same story.
A Semax research peptide product page should answer a practical procurement question: what can a laboratory buyer verify before making a research-material decision? The answer is documentation, not claims.
A literature review summarizes published research. A product-page research guide helps buyers evaluate a specific research material listing, its documentation, and its supplier records.
That distinction matters. Literature can discuss experimental models, but a product page should not turn model-specific findings into claims about a listed material.
Catalog language should be exact and restrained. For Semax, the safest catalog emphasis is compound identity, research category, COA availability, analytical testing, lot-level documentation, and RUO labeling.
This helps the page serve commercial research intent without drifting into non-RUO positioning. The product page should help qualified buyers compare documentation quality.
Buy Semax for research searches should be reframed around research procurement. A qualified buyer should ask whether the material is clearly labeled, whether batch-level records are available, and whether the COA supports the listed identity.
The search journey should end in review, not expectation-setting. That is the central RUO boundary.
Published Semax literature describes a synthetic heptapeptide related to ACTH-fragment research [3]. Additional work has examined Semax degradation, neurotrophin-related expression, and model-specific signaling contexts [4] [5].
A heptapeptide contains seven amino acid residues. Semax fits that classification through the sequence Met-Glu-His-Phe-Pro-Gly-Pro [2].
The analog classification matters because it places Semax in a specific peptide-research lane. It should not be generalized into unrelated peptide categories or product-claim language.
Molecular weight helps researchers compare a supplier listing with independent compound records. PubChem reports Semax with an approximate molecular weight of 813.9 g/mol for the ACTH (4-7), Pro-Gly-Pro record [1].
This is a documentation check, not a quality conclusion by itself. A matching molecular weight can support identity review, but it does not replace batch-specific analytical testing.
Published literature describes Semax as containing an ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro segment [7]. That Pro-Gly-Pro context appears in research on degradation and neurotrophin-related gene expression [4] [7].
For product-page writing, this detail belongs in compound identity and literature context. It should not be framed as a product-performance claim.
Semax literature includes central signaling, neurotrophin, monoamine-related, and gene expression research contexts [6] [8] [9]. Each context should be interpreted as model-specific literature.
Published studies have examined Semax in relation to BDNF, TrkB, serotonergic markers, and dopaminergic-system parameters in preclinical research settings [6] [9]. These are research model observations.
A product-page guide should describe that literature as background only. It should not imply that a supplier material produces the same findings in any non-research setting.
Semax literature includes studies on BDNF expression and neurotrophin receptor gene expression [5] [7]. A genome-wide transcriptional analysis also reported altered immune- and vascular-system gene expression in a preclinical focal ischemia model [8].
Those terms belong in a research interpretation section. They should be tied to the study design and kept separate from claims about a listed RUO material.
A pathway can be relevant to literature without becoming a claim about a product. For Semax, references to BDNF, gene expression, neurotransmitter-related signaling, or vascular context should remain attached to the specific studies that examined them [5] [8] [9].
The practical page rule is simple: pathway relevance informs research context; it does not define intended application.
The Semax evidence landscape includes compound identity databases, PubMed-indexed studies, in vitro work, preclinical models, and analytical chemistry sources. Research buyers should evaluate each evidence type by asking what it can show and what it cannot show.
Preclinical Semax literature can show model-specific changes in gene expression, neurotrophin markers, or neurotransmitter-related parameters under defined study conditions [7] [8] [9]. It cannot establish a product-page claim for RUO materials.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Formula, molecular weight, synonyms, and identifier records for Semax [1] [2] | Official database | Supports identity comparison, not a standalone quality conclusion |
| ACTH-fragment context | Semax classification as an ACTH-fragment analog [3] | PubMed-indexed literature | Supports research classification |
| Neurotrophin context | BDNF and related receptor expression in model-specific studies [5] [7] | Preclinical literature | Useful for literature context only |
| Gene expression context | Immune- and vascular-system gene expression in a defined model [8] | Transcriptomic study | Does not translate into product claims |
| In vitro molecular context | Semax interaction research in copper-complex fibrillogenesis models [10] | In vitro research | Supports mechanistic discussion only |
| Analytical review | HPLC and LC-HRMS as peptide analysis tools [11] [12] | Analytical chemistry | Supports documentation review |
A strong source-quality filter starts with official databases, peer-reviewed literature, and analytical chemistry methods. PubChem and NCATS help with identity records, while PubMed-indexed studies support literature context [1] [2] [8].
Vendor pages, forums, and unsourced summaries should not be treated as scientific support. Product-page copy should lean on verifiable sources.
Semax literature is not one uniform evidence block. It spans different models, endpoints, methods, and study aims, so findings should be interpreted within their original study context [6] [8] [10].
The safest interpretation is narrow. A study can support a sentence about what researchers examined, but not a broad claim about a research material listing.
Research literature and product claims serve different purposes. Literature describes experiments; product-page copy should describe RUO status, identity, documentation, analytical testing, and procurement review.
Study findings depend on model design, endpoints, measurement tools, and experimental context. For example, Semax gene expression research and in vitro molecular research address specific questions within controlled settings [8] [10].
Product-page copy should not strip those findings away from their context. The safer phrase is “published literature has examined,” not “the product does.”
Claim boundaries keep a research page from implying non-RUO intent. Semax product-page copy should avoid converting terms from literature into claims about listed material.
For Pure Lab Peptides, RUO positioning means the content should direct attention back to COA review, identity verification, lot traceability, supplier documentation, and research-only labeling.
Product documentation is the best anchor for a research product page. It keeps the page practical: what is the compound, what batch is being referenced, what testing is listed, and what records can a lab retain?
This also supports compliance. Documentation-centered writing is less likely to drift into outcome language.
A certificate of analysis is the central batch-level document for Semax research procurement. It should help a buyer confirm what material was tested, what methods were listed, and which lot the results belong to.
A Semax COA should be reviewed for compound name, lot number, assay purity, testing method, identity method, test date, and lab or reviewer information. Analytical validation guidance from FDA Q2(R2) emphasizes method validation principles, including the evaluation of analytical procedures and spectroscopic data where relevant [13].
A COA should be batch-specific. A generic document is less useful for procurement review because it cannot clearly connect data to the material being evaluated.
COA dates and lot numbers support traceability. The lot number should match the label, product record, and any batch-specific test documentation.
If a lab stores procurement records, the COA date helps clarify which test record was reviewed at the time of selection. That improves auditability and internal consistency.
Purity and identity are related, but they are not the same. A Semax material can show a high purity value while still requiring a separate identity review.
HPLC is widely used in peptide analysis and purification, including reversed-phase, ion-exchange, and size-exclusion approaches for peptide separation [11]. On a COA, HPLC data can help support a purity review when the method and chromatogram information are available.
HPLC should be read as part of a documentation package. It is more informative when linked to the lot number, method notes, and reviewer record.
LC-MS pairs liquid chromatography with mass spectrometry, allowing peptide-related identity and impurity characterization through mass-based information [12]. For Semax, LC-MS support is useful because peptide identity depends on the expected molecular mass and related analytical data.
A strong documentation package should make the connection clear. The listed compound, expected mass, analytical result, and lot record should align.
Analytical review is not a single checkbox. It is a sequence of record matching, method review, data interpretation, and documentation retention.
Numbered lab-test verification protocol:
Reference standards can improve analytical review by giving the method a defined comparator. FDA Q14 describes scientific approaches for analytical procedure development and emphasizes risk-based, science-based method understanding [14].
For research procurement, the point is not to overstate certainty. The point is to ask whether the documentation gives enough method context for a qualified technical review.
Lot traceability connects the product listing to the material record. For Semax, that connection should run through the label, COA, testing record, and any storage documentation.
Lot traceability helps prevent document ambiguity. If a COA lists one lot and the label lists another, the documentation package cannot be treated as internally consistent.
Traceability also supports repeat review. A lab team should be able to return to the record and see which Semax batch was evaluated and what evidence supported the procurement decision.
Label consistency makes technical procurement cleaner. The compound name, lot number, research-use-only designation, and storage statement should align with the COA and listing details.
This is especially important when a product page includes several scientific identifiers. Multiple synonyms are useful only when they are consistently tied to the same compound record.
Supplier review should not be based on marketing language. It should be based on documentation clarity, analytical transparency, and RUO consistency.
Quality and documentation checklist:
Lyophilized material documentation belongs in the storage and handling record. Freeze-drying removes water from a frozen sample through sublimation and desorption, and peptide stability can depend on intrinsic and external factors such as temperature, pH, concentration, and formulation environment [15] [16].
For Semax research procurement, the key question is whether the supplier gives clear documentation. Storage statements should be recorded as part of the lab’s material file, not converted into product claims.
Semax product-page research can become unclear when literature context, commercial intent, and documentation review are mixed together. The safer approach is to separate them.
Common misunderstandings include:
These distinctions protect the integrity of the page and keep Semax in a research-use-only context.
Selank belongs only as a same-lane research entity when Semax content needs category context. It should not be used to blur compound identity or stack unrelated keywords.
For a Semax product-page guide, Selank is best handled as a separate peptide-research reference point. The main entity remains Semax.
A final procurement review should return to the same core questions: Is the compound identity clear, is the COA batch-specific, is testing documented, and does the page remain RUO-focused?
Before technical procurement, researchers should confirm the product listing, COA, label, lot number, and analytical documentation. Recent review literature on peptide and biologic analysis notes that FDA, ICH, and EMA guidance frameworks are central to quality-control and stability-testing discussions [18].
For Semax, the buyer’s practical file should include the listing snapshot, COA, label record, lot details, testing notes, and storage statement. Hoofnagle and colleagues also describe consensus recommendations for peptide procurement, characterization, storage, and handling in mass-spectrometry-based assay contexts [17].
RUO framing should remain consistent from search intent to final documentation review. “Buy Semax for research” should mean evaluating a research material listing through identity, purity, COA, and lot-traceability records.
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
Researchers should consider documentation first before they buy Semax for research. A research-focused review should confirm RUO labeling, batch-specific COA availability, lot traceability, peptide identity, purity data, and supplier documentation. The procurement question is not outcome-based; it is whether the product record gives a qualified research team enough information for technical review.
Semax is described in research literature as a synthetic regulatory peptide related to an ACTH-fragment context. Product-page discussion should keep that description tied to compound identity, peptide classification, and published literature, not claims about application. Sequence, molecular weight, synonym records, and analytical documentation help support a clear research-material review [1] [2].
Adrenocorticotropic hormone context is relevant because Semax is commonly discussed as an ACTH-fragment analog in research literature. For documentation review, that context helps researchers compare compound naming, synonym records, and classification language. It should remain a peptide identity and literature-context detail, not a claim about the listed RUO material [3].
Researchers might review brain-derived neurotrophic factor literature because some published Semax studies examine BDNF-related markers in model-specific research settings. That literature can help frame research questions and evidence limits. It should not be converted into product-positioning language, and it should remain separate from COA review, analytical testing, and lot-level documentation [5] [7].
Central nervous system literature can provide background for how Semax has been examined in neuropeptide research models. The safer interpretation is narrow: published findings describe study conditions, model design, and measured endpoints. A product-page FAQ should keep that context separate from product claims and redirect attention to RUO labeling, compound identity, and documentation review.
Research teams should evaluate the source of Semax materials by reviewing supplier documentation, batch-specific COA records, label consistency, and analytical testing support. A reliable review compares product records against identity data and lot-level documentation. The focus should remain on research-material traceability, not promotional language or non-RUO positioning.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: Frontiers Loop
Oleg V. Dolotov is a research author whose published work is relevant to Semax, ACTH-fragment peptide literature, and neurotrophin-focused research models. His publications help inform the article’s discussion of Semax as a synthetic peptide in neuropeptide research, with emphasis on BDNF-related literature, peptide classification, and model-specific interpretation. This work also supports the broader scientific context for research peptides where compound identity and published literature need to remain separate from product-page claims.
Selected publications:
Author profile: ResearchGate
Ekaterina V. Medvedeva is recognized for publications connected to Semax gene-expression research and ACTH-fragment peptide literature. Her work is relevant to the article’s discussion of model-specific evidence, vascular-system gene-expression context, and the need to interpret published findings as research literature rather than product positioning. These publications provide useful background for Semax research pages that focus on compound context, documentation review, and careful separation between literature findings and RUO product claims.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Semax. In neuropeptide research content, terms such as nootropic, cognitive enhancement, mental clarity, brain health, nasal spray, peptide therapy, and neuroprotective effects can drift into consumer-facing, wellness, clinical-use, or product-claim language when framed incorrectly. Phrases such as effects of Semax, efficacy of Semax, Semax administration, ischemic stroke, and dopamine and serotonin also require careful separation from product positioning because they can imply claims outside model-specific research context.
Here, those phrases are handled only as research-language examples, not product claims, intended outcomes, instructions, or recommendations. The focus remains on Semax identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and published literature boundaries. This page is structured for research procurement and documentation review, with scientific terminology interpreted through compound characterization, model-specific evidence, and research-use-only labeling.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.